Thuresson, Marcus

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

Jernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M., & Janzon, M. (2015) · European Heart Journal

Acute Myocardial Infarction ResearchCardiac Health and Mental Health

Cited by 875

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 813

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

Heerspink, H. J. L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., Wilding, J. P. H., Garcia Rodriguez, L. A., Cea-Soriano, L., Kohsaka, S., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 317

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study

Birkeland, K. I., Bodegard, J., Eriksson, J. W., Norhammar, A., Haller, H., Linssen, G. C. M., Banerjee, A., Thuresson, M., Okami, S., Garal‐Pantaler, E., et al. (2020) · Diabetes, Obesity and Metabolism

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 223

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( CVD‐REAL Nordic ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: Amultinational observational study

Persson, F., Nyström, T., Jørgensen, M. E., Carstensen, B., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J. W., Norhammar, A., et al. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 212

Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR)

Larsson, K., Ställberg, B., Lisspers, K., Telg, G., Johansson, G., Thuresson, M., & Janson, C. (2018) · Respiratory Research

Asthma and respiratory diseasesChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 100

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 94

Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence

McEwan, P., Bennett, H., Khunti, K., Wilding, J., Edmonds, C., Thuresson, M., Wittbrodt, E., Fenici, P., & Kosiborod, M. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 58